The quarter was good in that they didn't have anything negative at a time when a lot of people are wary about earnings,
There are some names out there, like Wyeth, for example, that, you know, the base business is in good enough shape, where they actually don't need much coming out of the pipeline,
The real pivotal one will be Claritin, ... You could see some very good growth there.
This is a pretty good deal for King. It brings them into new therapeutic areas and shows management is aggressive.
I had the good fortune of knocking my 2-3-foot putt in on the last hole and Doug's just burnt the edge. He was a great competitor.
It was a good quarter and quiet with no surprises, which is never a bad thing.
Anything that moves it forward is a good thing, and this looks like it's moving forward.
You've got the good with the bad with the sector, ... The good being that you've got good products and fundamentals and the bad being that you've got some negative headlines.
We expect the company to put up a good show, give guidance that is ahead of consensus and not have any significant negative surprises.